Quick Answer
Petros Pharmaceuticals, Inc. reported Total Revenue of $5.99 million for fiscal year 2022.
Petros Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | $5.99M -23.3% |
$7.81M -18.3% |
$9.56M | — |
| Revenue (ASC 606) | — | — | $5.99M -23.3% |
$7.81M -18.3% |
$9.56M | — |
| Net Income | -$14.32M -75.4% |
-$8.16M +59.3% |
-$20.04M -123.0% |
-$8.99M +56.3% |
-$20.59M | — |
| Diluted EPS | -$3.34 +47.4% |
-$6.35 +34.4% |
-$9.68 -17.3% |
-$8.25 -114.3% |
-$3.85 | — |
| Total Assets | $10.64M -68.5% |
$33.80M +4.2% |
$32.42M -51.9% |
$67.39M -3.5% |
$69.85M | — |
| Cash and Equivalents | $3.71M -72.2% |
$13.34M +41.5% |
$9.43M -60.5% |
$23.85M +39.1% |
$17.14M | — |
| Stockholders Equity | -$7.47M -161.9% |
$12.07M -27.7% |
$16.70M -53.0% |
$35.54M +103.5% |
$17.47M +117.8% |
$8.02M |
| R&D Expense | $2.62M +8.5% |
$2.41M +38.4% |
$1.74M -2.7% |
$1.79M +289.1% |
$459.6K | — |
| Operating Income | -$17.68M -29.8% |
-$13.62M +31.6% |
-$19.92M -10.3% |
-$18.05M -4.4% |
-$17.28M | — |
| Gross Profit | $3.90M -7.0% |
$4.19M +13.2% |
$3.70M -40.4% |
$6.21M +12.7% |
$5.51M | — |
| Shares Outstanding | 10.53M +251.9% |
2.99M +43.9% |
2.08M +0.5% |
2.07M -78.7% |
9.71M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2023 | $1.99M | -52.4% | -20.8% |
| Revenue (ASC 606) | June 30, 2023 | $1.99M | -52.4% | -20.8% |
| Net Income | September 30, 2025 | -$922.7K | +58.4% | -117.0% |
| Diluted EPS | September 30, 2025 | -$0.03 | +99.8% | +97.7% |
| Total Assets | September 30, 2025 | $6.13M | -70.4% | -17.1% |
| Cash and Equivalents | September 30, 2025 | $6.07M | — | -17.1% |
| Stockholders Equity | September 30, 2025 | $3.37M | +8.1% | -24.3% |
| R&D Expense | September 30, 2024 | $588.4K | +51.2% | +59.5% |
| Operating Income | September 30, 2025 | -$990.7K | +17.3% | +45.0% |
| Gross Profit | September 30, 2024 | $1.29M | +1.8% | +18.0% |
| Shares Outstanding | September 30, 2025 | 42.28M | +322.2% | +0.0% |
- Petros Pharmaceuticals, Inc. reported Total Revenue of $5.99 million for fiscal year 2022.
- Petros Pharmaceuticals, Inc. showed a decrease of -23.3% in Total Revenue compared to the prior fiscal year.
- Petros Pharmaceuticals, Inc. reported Revenue (ASC 606) of $5.99 million for fiscal year 2022.
- Petros Pharmaceuticals, Inc. showed a decrease of -23.3% in Revenue (ASC 606) compared to the prior fiscal year.
- Petros Pharmaceuticals, Inc. reported Net Income of -$14.32 million for fiscal year 2024.
- Petros Pharmaceuticals, Inc. showed a decrease of -75.4% in Net Income compared to the prior fiscal year.
- Petros Pharmaceuticals, Inc. reported Diluted EPS of $3.34 per share (loss) for fiscal year 2024.
- Petros Pharmaceuticals, Inc. showed an increase of +47.4% in Diluted EPS compared to the prior fiscal year.
- Petros Pharmaceuticals, Inc. reported Total Assets of $10.64 million for fiscal year 2024.
- Petros Pharmaceuticals, Inc. showed a decrease of -68.5% in Total Assets compared to the prior fiscal year.
- Petros Pharmaceuticals, Inc. reported Cash and Equivalents of $3.71 million for fiscal year 2024.
- Petros Pharmaceuticals, Inc. showed a decrease of -72.2% in Cash and Equivalents compared to the prior fiscal year.
- Petros Pharmaceuticals, Inc. reported Stockholders Equity of -$7.47 million for fiscal year 2024.
- Petros Pharmaceuticals, Inc. showed a decrease of -161.9% in Stockholders Equity compared to the prior fiscal year.
- Petros Pharmaceuticals, Inc. reported R&D Expense of $2.62 million for fiscal year 2024.
- Petros Pharmaceuticals, Inc. showed an increase of +8.5% in R&D Expense compared to the prior fiscal year.
- Petros Pharmaceuticals, Inc. reported Operating Income of -$17.68 million for fiscal year 2024.
- Petros Pharmaceuticals, Inc. showed a decrease of -29.8% in Operating Income compared to the prior fiscal year.
- Petros Pharmaceuticals, Inc. reported Gross Profit of $3.90 million for fiscal year 2024.
- Petros Pharmaceuticals, Inc. showed a decrease of -7.0% in Gross Profit compared to the prior fiscal year.
- Petros Pharmaceuticals, Inc. reported Shares Outstanding of 10.53 million shares for fiscal year 2024.
- Petros Pharmaceuticals, Inc. showed an increase of +251.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: